TL;DR
This study investigates the anti-inflammatory effects of dasatinib, a drug approved for chronic myeloid leukemia, on brain immune cells. The research demonstrates that dasatinib can suppress LPS-induced inflammation in microglia and astrocytes by inhibiting key signaling pathways (AKT/STAT3 and TLR4), suggesting its potential as a therapeutic agent for neuroinflammatory diseases.
What Problem Does This Paper Address?
Neuroinflammation, characterized by the overactivation of immune cells in the brain like microglia and astrocytes, is a significant contributor to neurodegenerative diseases such as Alzheimer's. Lipopolysaccharide (LPS) is a common tool used to induce experimental neuroinflammation, mimicking bacterial infection or inflammatory triggers. While dasatinib is known for its immunomodulatory properties and ability to cross the blood-brain barrier, its specific effects on LPS-induced neuroinflammation in microglia and astrocytes, and the underlying molecular mechanisms, were not well understood. This paper aims to fill that knowledge gap by exploring how dasatinib impacts these crucial brain immune cells and their inflammatory responses.
Methods
The researchers employed a multi-pronged approach:
- In vitro studies: They used established cell lines (BV2 microglial cells) and primary cultures of mouse and rat microglia and astrocytes. These cells were treated with dasatinib and/or LPS, followed by various analyses.
- Molecular Biology Techniques:
- RT-PCR and Real-time PCR: Used to measure the mRNA levels of pro-inflammatory (e.g., COX-2, IL-6, IL-1β, TNF-α, iNOS) and anti-inflammatory cytokines.
- Western Blotting: Employed to assess the protein levels and phosphorylation status of key signaling molecules like AKT, ERK, and STAT3.
- Immunocytochemistry: Utilized to visualize the localization and expression of specific proteins (e.g., p-STAT3, COX-2, CD11b) within the cells.
- Subcellular Fractionation: Performed to distinguish between cytosolic and nuclear protein levels, particularly for p-STAT3.
- Cell Surface Biotinylation: Used to investigate changes in the cell surface expression of TLR4.
- MTT and BrdU Assays: Standard assays to evaluate cell viability and proliferation, respectively, to ensure dasatinib's effects weren't due to general toxicity.
- Griess Assay: A colorimetric assay to measure nitrite (NO) production, a marker of inflammation.
- In vivo studies: Wild-type mice were used to assess dasatinib's effects in a living organism.
- Administration Routes: Dasatinib was administered via intraperitoneal (i.p.) injection and oral gavage (p.o.).
- Treatment Regimens: Both short-term (4 days) and longer-term (2 weeks) treatment protocols were used.
- LPS Challenge: Mice were injected with LPS to induce neuroinflammation.
- Immunohistochemistry: Brain tissues were analyzed to assess microglial (Iba-1) and astrocytic (GFAP) activation, as well as the expression of inflammatory markers (COX-2, IL-6) and markers of neutrophil infiltration (Ly-6B, ICAM-1).
- ELISA: Used to measure the levels of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) in mouse plasma.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- Dasatinib as a Neuroinflammation Modulator: The study strongly suggests that dasatinib, beyond its known anti-cancer roles, can actively dampen neuroinflammatory responses triggered by LPS.
- Targeting Key Signaling Pathways: A central finding is that dasatinib works by inhibiting crucial signaling cascades like AKT/STAT3 and TLR4, which are central to the inflammatory cascade. This provides a mechanistic explanation for its observed effects.
- Differential Effects Based on Glucose Levels: The study highlights that dasatinib's impact on certain inflammatory markers in primary microglial cells can vary depending on whether the cells are cultured in low or high glucose conditions, suggesting context-dependent efficacy.
- Pre-treatment is More Effective: For BV2 microglial cells, pre-treating with dasatinib before LPS exposure was found to be more effective in reducing inflammatory responses than post-treatment.
- Modulation of Anti-inflammatory Pathways: Beyond suppressing pro-inflammatory responses, dasatinib also appears to upregulate anti-inflammatory cytokine expression (IL-4, IL-10) in some contexts.
- In Vivo Efficacy: The findings in cell cultures were largely recapitulated in animal models, showing that both i.p. and oral administration of dasatinib can reduce neuroinflammation, microglial/astrocyte activation, and cytokine release in the brain and plasma.
Key Results
- In vitro:
- Dasatinib (up to 250 nM) did not show cytotoxicity or inhibit proliferation in BV2 microglial cells or primary astrocytes.
- Dasatinib significantly suppressed LPS-induced mRNA levels of COX-2, IL-6, and TNF-α in BV2 microglial cells.
- Dasatinib inhibited LPS-induced phosphorylation of AKT and ERK in BV2 microglial cells and primary astrocytes.
- Dasatinib reduced LPS-induced nuclear p-STAT3 levels in BV2 microglial cells and primary astrocytes.
- Dasatinib treatment led to decreased levels of COX-2 and IL-6 mRNA in primary astrocytes under both low and high glucose conditions.
- In vivo:
- Intraperitoneal and oral administration of dasatinib significantly reduced LPS-induced microglial (Iba-1) and astrocytic (GFAP) activation in the hippocampus of wild-type mice.
- Dasatinib significantly suppressed LPS-induced COX-2 and IL-6 levels in the cortex and hippocampus of wild-type mice.
- Oral administration of dasatinib significantly reduced plasma levels of TNF-α and IL-1β in LPS-injected wild-type mice.
- Dasatinib showed a tendency to decrease LPS-induced neutrophil rolling in the CNS vasculature.
Limitations and Future Work
- Glucose Dependence: The study noted that dasatinib's effects on certain inflammatory markers in primary microglial cells varied with glucose concentration. Further investigation into the mechanisms behind this glucose-dependent regulation is warranted.
- STAT3 Signaling Nuance: While dasatinib significantly reduced LPS-induced STAT3 phosphorylation, the study suggests that its effects on COX-2 and IL-6 mRNA levels were only partially dependent on STAT3 signaling. This implies that other transcription factors or signaling pathways are also involved and warrant further exploration.
- Mechanistic Elucidation: The authors propose that dasatinib's effects are mediated through TLR4/ERK/AKT/STAT3 signaling. However, they acknowledge the need for further studies using shRNA or knockout models to definitively confirm the roles of TLR4, ERK, and AKT in mediating dasatinib's anti-inflammatory actions.
- Broader Therapeutic Potential: While the study focuses on LPS-induced inflammation, the authors suggest that dasatinib's ability to modulate neuroinflammation could make it a valuable therapeutic agent for neurodegenerative diseases like Alzheimer's and CNS leukemia, which warrants further clinical investigation.
Summary updated